- Home
- IOVA vs NEA Comparison
IOVA vs NEA Comparison
Compare IOVA & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- NEA
- Stock Information
- Founded
- IOVA 2007
- NEA 2002
- Country
- IOVA United States
- NEA United States
- Employees
- IOVA N/A
- NEA N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- NEA Finance/Investors Services
- Sector
- IOVA Health Care
- NEA Finance
- Exchange
- IOVA Nasdaq
- NEA Nasdaq
- Market Cap
- IOVA 975.1M
- NEA 3.4B
- IPO Year
- IOVA N/A
- NEA N/A
- Fundamental
- Price
- IOVA $2.22
- NEA $11.32
- Analyst Decision
- IOVA Buy
- NEA
- Analyst Count
- IOVA 11
- NEA 0
- Target Price
- IOVA $11.90
- NEA N/A
- AVG Volume (30 Days)
- IOVA 9.5M
- NEA 803.4K
- Earning Date
- IOVA 11-06-2025
- NEA 01-01-0001
- Dividend Yield
- IOVA N/A
- NEA 4.23%
- EPS Growth
- IOVA N/A
- NEA N/A
- EPS
- IOVA N/A
- NEA N/A
- Revenue
- IOVA $241,525,000.00
- NEA N/A
- Revenue This Year
- IOVA $67.40
- NEA N/A
- Revenue Next Year
- IOVA $56.32
- NEA N/A
- P/E Ratio
- IOVA N/A
- NEA N/A
- Revenue Growth
- IOVA 636.99
- NEA N/A
- 52 Week Low
- IOVA $1.64
- NEA $9.20
- 52 Week High
- IOVA $12.51
- NEA $11.37
- Technical
- Relative Strength Index (RSI)
- IOVA 43.75
- NEA 64.38
- Support Level
- IOVA $2.27
- NEA $10.92
- Resistance Level
- IOVA $2.38
- NEA $11.46
- Average True Range (ATR)
- IOVA 0.14
- NEA 0.08
- MACD
- IOVA -0.01
- NEA 0.02
- Stochastic Oscillator
- IOVA 28.21
- NEA 74.07
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.